Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness

BACKGROUND: Vedolizumab (VDZ) is a humanized monoclonal IgG1 antibody which inhibits leukocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. AIMS: We retrospectively assessed the 12-month, real-world efficacy and safety of VDZ as induction and mainte...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Can Assoc Gastroenterol
Autors principals: Zezos, Petros, Kabakchiev, Boyko, Weizman, Adam V, Nguyen, Geoffrey C, Narula, Neeraj, Croitoru, Kenneth, Steinhart, A Hillary, Silverberg, Mark S
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7165264/
https://ncbi.nlm.nih.gov/pubmed/32328546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy065
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars